Skip to content

Study · Animal study (in vivo) · rat · 2016

10 results

BPC 157: The counteraction of succinylcholine, hyperkalemia, and arrhythmias.

Stambolija V, Stambolija TP, Holjevac JK, Murselovic T, Radonic J, Duzel V, Duplancic B, Uzun S, Zivanovic-Posilovic G, Kolenc D, Drmic D, Romic Z, Seiwerth S, Sikiric P

European journal of pharmacology6 Apr 2016Cited by 32 (Europe PMC)

PMID27060013 (opens in a new tab)DOI10.1016/j.ejphar.2016.04.004 (opens in a new tab)PepBankPUB-27060013
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats given succinylcholine, BPC‑157 completely eliminated hyperkalemia.

    In plain wordsIn rats given succinylcholine, BPC‑157 completely eliminated high blood potassium.

    Peptide
    BPC-157
    Outcome
    DecreaseSuccinylcholine-induced hyperkalemia
    Study

    ratn: not reported in source

    Outcome group
    Electrolyte balance · Whole body
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal or drinking waterAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 completely eliminated hyperkalemia and arrhythmias
    2 context sentences
    Summary · context
    Assessments were made at 3 and 30min and 1, 3, 5, and 7 days after succinylcholine administration (1.0mg/kg into the right anterior tibial muscle).
    Summary · context
    BPC 157 (10µg/kg, 10ng/kg) (given intraperitoneally 30min before or immediately after succinylcholine or per-orally in drinking water through 24h until succinylcholine administration) mitigated both local and systemic disturbances.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats given succinylcholine, BPC‑157 completely eliminated arrhythmias.

    In plain wordsIn rats given succinylcholine, BPC‑157 completely eliminated heart rhythm disturbances.

    Peptide
    BPC-157
    Outcome
    DecreaseSuccinylcholine-induced arrhythmias
    Study

    ratn: not reported in source

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal or drinking waterAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 completely eliminated hyperkalemia and arrhythmias
    2 context sentences
    Summary · context
    Assessments were made at 3 and 30min and 1, 3, 5, and 7 days after succinylcholine administration (1.0mg/kg into the right anterior tibial muscle).
    Summary · context
    BPC 157 (10µg/kg, 10ng/kg) (given intraperitoneally 30min before or immediately after succinylcholine or per-orally in drinking water through 24h until succinylcholine administration) mitigated both local and systemic disturbances.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats given succinylcholine, BPC‑157 counteracted the rise in serum enzyme values.

    In plain wordsIn rats given succinylcholine, BPC‑157 counteracted the rise in blood enzyme values.

    Peptide
    BPC-157
    Outcome
    DecreaseSerum enzyme rise after succinylcholine
    Study

    ratn: not reported in source

    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal or drinking waterAs given in this study (rat).

    Source sentences

    Summary
    Hyperkalemia, arrhythmias and a rise in serum enzyme values, were counteracted in rats.
    2 context sentences
    Summary · context
    Assessments were made at 3 and 30min and 1, 3, 5, and 7 days after succinylcholine administration (1.0mg/kg into the right anterior tibial muscle).
    Summary · context
    BPC 157 (10µg/kg, 10ng/kg) (given intraperitoneally 30min before or immediately after succinylcholine or per-orally in drinking water through 24h until succinylcholine administration) mitigated both local and systemic disturbances.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats given succinylcholine, BPC‑157 markedly attenuated or eradicated behavioral agitation.

    In plain wordsIn rats given succinylcholine, BPC‑157 markedly reduced or removed agitated behavior.

    Peptide
    BPC-157
    Outcome
    DecreaseBehavioral agitation after succinylcholine
    Study

    ratn: not reported in source

    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal or drinking waterAs given in this study (rat).

    Source sentences

    Summary
    markedly attenuated or erradicated behavioral agitation, muscle twitches, motionless resting
    2 context sentences
    Summary · context
    Assessments were made at 3 and 30min and 1, 3, 5, and 7 days after succinylcholine administration (1.0mg/kg into the right anterior tibial muscle).
    Summary · context
    BPC 157 (10µg/kg, 10ng/kg) (given intraperitoneally 30min before or immediately after succinylcholine or per-orally in drinking water through 24h until succinylcholine administration) mitigated both local and systemic disturbances.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats given succinylcholine, BPC‑157 markedly attenuated or eradicated muscle twitches.

    In plain wordsIn rats given succinylcholine, BPC‑157 markedly reduced or removed muscle twitches.

    Peptide
    BPC-157
    Outcome
    DecreaseMuscle twitches after succinylcholine
    Study

    ratn: not reported in source

    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal or drinking waterAs given in this study (rat).

    Source sentences

    Summary
    markedly attenuated or erradicated behavioral agitation, muscle twitches, motionless resting
    2 context sentences
    Summary · context
    Assessments were made at 3 and 30min and 1, 3, 5, and 7 days after succinylcholine administration (1.0mg/kg into the right anterior tibial muscle).
    Summary · context
    BPC 157 (10µg/kg, 10ng/kg) (given intraperitoneally 30min before or immediately after succinylcholine or per-orally in drinking water through 24h until succinylcholine administration) mitigated both local and systemic disturbances.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats given succinylcholine, BPC‑157 markedly attenuated or eradicated motionless resting.

    In plain wordsIn rats given succinylcholine, BPC‑157 markedly reduced or removed motionless resting.

    Peptide
    BPC-157
    Outcome
    DecreaseMotionless resting after succinylcholine
    Study

    ratn: not reported in source

    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal or drinking waterAs given in this study (rat).

    Source sentences

    Summary
    markedly attenuated or erradicated behavioral agitation, muscle twitches, motionless resting
    2 context sentences
    Summary · context
    Assessments were made at 3 and 30min and 1, 3, 5, and 7 days after succinylcholine administration (1.0mg/kg into the right anterior tibial muscle).
    Summary · context
    BPC 157 (10µg/kg, 10ng/kg) (given intraperitoneally 30min before or immediately after succinylcholine or per-orally in drinking water through 24h until succinylcholine administration) mitigated both local and systemic disturbances.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats given succinylcholine, BPC‑157 completely eliminated post-succinylcholine hyperalgesia.

    In plain wordsIn rats given succinylcholine, BPC‑157 completely eliminated the increased pain sensitivity that followed.

    Peptide
    BPC-157
    Outcome
    DecreasePost-succinylcholine hyperalgesia
    Study

    ratn: not reported in source

    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal or drinking waterAs given in this study (rat).

    Source sentences

    Summary
    completely eliminated post-succinylcholine hyperalgesia.
    2 context sentences
    Summary · context
    Assessments were made at 3 and 30min and 1, 3, 5, and 7 days after succinylcholine administration (1.0mg/kg into the right anterior tibial muscle).
    Summary · context
    BPC 157 (10µg/kg, 10ng/kg) (given intraperitoneally 30min before or immediately after succinylcholine or per-orally in drinking water through 24h until succinylcholine administration) mitigated both local and systemic disturbances.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rats given succinylcholine, BPC‑157 immediately eliminated leg contractures.

    In plain wordsIn rats given succinylcholine, BPC‑157 immediately eliminated leg contractures.

    Peptide
    BPC-157
    Outcome
    DecreaseLeg contractures after succinylcholine
    Study

    ratn: not reported in source

    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal or drinking waterAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 immediately eliminated leg contractures and counteracted both edema and the decrease in muscle fibers in the diaphragm and injected/non-injected anterior tibial muscles.
    2 context sentences
    Summary · context
    Assessments were made at 3 and 30min and 1, 3, 5, and 7 days after succinylcholine administration (1.0mg/kg into the right anterior tibial muscle).
    Summary · context
    BPC 157 (10µg/kg, 10ng/kg) (given intraperitoneally 30min before or immediately after succinylcholine or per-orally in drinking water through 24h until succinylcholine administration) mitigated both local and systemic disturbances.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In rats given succinylcholine, BPC‑157 counteracted edema in the diaphragm and in injected and non-injected anterior tibial muscles.

    In plain wordsIn rats given succinylcholine, BPC‑157 counteracted swelling in the diaphragm and leg muscles.

    Peptide
    BPC-157
    Outcome
    DecreaseMuscle edema after succinylcholine
    Study

    ratn: not reported in source

    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal or drinking waterAs given in this study (rat).

    Source sentences

    Summary
    counteracted both edema and the decrease in muscle fibers in the diaphragm and injected/non-injected anterior tibial muscles.
    2 context sentences
    Summary · context
    Assessments were made at 3 and 30min and 1, 3, 5, and 7 days after succinylcholine administration (1.0mg/kg into the right anterior tibial muscle).
    Summary · context
    BPC 157 (10µg/kg, 10ng/kg) (given intraperitoneally 30min before or immediately after succinylcholine or per-orally in drinking water through 24h until succinylcholine administration) mitigated both local and systemic disturbances.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In rats given succinylcholine, BPC‑157 counteracted the decrease in muscle fibers in the diaphragm and in injected and non-injected anterior tibial muscles.

    In plain wordsIn rats given succinylcholine, BPC‑157 counteracted the loss of muscle fibers in the diaphragm and leg muscles.

    Peptide
    BPC-157
    Outcome
    IncreaseMuscle fiber loss after succinylcholine
    Study

    ratn: not reported in source

    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitoneal or drinking waterAs given in this study (rat).

    Source sentences

    Summary
    counteracted both edema and the decrease in muscle fibers in the diaphragm and injected/non-injected anterior tibial muscles.
    2 context sentences
    Summary · context
    Assessments were made at 3 and 30min and 1, 3, 5, and 7 days after succinylcholine administration (1.0mg/kg into the right anterior tibial muscle).
    Summary · context
    BPC 157 (10µg/kg, 10ng/kg) (given intraperitoneally 30min before or immediately after succinylcholine or per-orally in drinking water through 24h until succinylcholine administration) mitigated both local and systemic disturbances.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.